Molecular testing in lung cancer

The time is now

Haiying Cheng, Xunhai Xu, Daniel B. Costa, Charles A. Powell, Balazs Halmos

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In the past few years, we have witnessed a revolution in the molecular understanding of non-small cell lung cancer. Major progress has also been made in the clinic, with the introduction of EGFR-targeted and anti-angiogenic therapies. These advances have led to the development of a multitude of commercially available prognostic and predictive biomarkers. In particular, EGFR mutation and EML4/ALK testing have reached clinical validation and are incorporated into current treatment paradigms. This overview will present the scientific background of the biology of the relevant biomarkers and the studies conducted for their clinical validation. The technical challenges and shortcomings of these assays are also discussed. Furthermore, ongoing biomarker-driven clinical studies and the appropriate clinical use of available tests will be reviewed to assist the clinician with the proper incorporation of molecular testing into the routine care of patients with non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)335-348
Number of pages14
JournalCurrent Oncology Reports
Volume12
Issue number5
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Lung Neoplasms
Biomarkers
Non-Small Cell Lung Carcinoma
Patient Care
Mutation
Therapeutics
Clinical Studies

Keywords

  • Biomarkers
  • EGFR
  • EML4/ALK translocation
  • KRAS
  • Molecular testing
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Molecular testing in lung cancer : The time is now. / Cheng, Haiying; Xu, Xunhai; Costa, Daniel B.; Powell, Charles A.; Halmos, Balazs.

In: Current Oncology Reports, Vol. 12, No. 5, 09.2010, p. 335-348.

Research output: Contribution to journalArticle

Cheng, Haiying ; Xu, Xunhai ; Costa, Daniel B. ; Powell, Charles A. ; Halmos, Balazs. / Molecular testing in lung cancer : The time is now. In: Current Oncology Reports. 2010 ; Vol. 12, No. 5. pp. 335-348.
@article{8b070e64db2e4a4097a44fd40612b928,
title = "Molecular testing in lung cancer: The time is now",
abstract = "In the past few years, we have witnessed a revolution in the molecular understanding of non-small cell lung cancer. Major progress has also been made in the clinic, with the introduction of EGFR-targeted and anti-angiogenic therapies. These advances have led to the development of a multitude of commercially available prognostic and predictive biomarkers. In particular, EGFR mutation and EML4/ALK testing have reached clinical validation and are incorporated into current treatment paradigms. This overview will present the scientific background of the biology of the relevant biomarkers and the studies conducted for their clinical validation. The technical challenges and shortcomings of these assays are also discussed. Furthermore, ongoing biomarker-driven clinical studies and the appropriate clinical use of available tests will be reviewed to assist the clinician with the proper incorporation of molecular testing into the routine care of patients with non-small cell lung cancer.",
keywords = "Biomarkers, EGFR, EML4/ALK translocation, KRAS, Molecular testing, Non-small cell lung cancer",
author = "Haiying Cheng and Xunhai Xu and Costa, {Daniel B.} and Powell, {Charles A.} and Balazs Halmos",
year = "2010",
month = "9",
doi = "10.1007/s11912-010-0118-z",
language = "English (US)",
volume = "12",
pages = "335--348",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Molecular testing in lung cancer

T2 - The time is now

AU - Cheng, Haiying

AU - Xu, Xunhai

AU - Costa, Daniel B.

AU - Powell, Charles A.

AU - Halmos, Balazs

PY - 2010/9

Y1 - 2010/9

N2 - In the past few years, we have witnessed a revolution in the molecular understanding of non-small cell lung cancer. Major progress has also been made in the clinic, with the introduction of EGFR-targeted and anti-angiogenic therapies. These advances have led to the development of a multitude of commercially available prognostic and predictive biomarkers. In particular, EGFR mutation and EML4/ALK testing have reached clinical validation and are incorporated into current treatment paradigms. This overview will present the scientific background of the biology of the relevant biomarkers and the studies conducted for their clinical validation. The technical challenges and shortcomings of these assays are also discussed. Furthermore, ongoing biomarker-driven clinical studies and the appropriate clinical use of available tests will be reviewed to assist the clinician with the proper incorporation of molecular testing into the routine care of patients with non-small cell lung cancer.

AB - In the past few years, we have witnessed a revolution in the molecular understanding of non-small cell lung cancer. Major progress has also been made in the clinic, with the introduction of EGFR-targeted and anti-angiogenic therapies. These advances have led to the development of a multitude of commercially available prognostic and predictive biomarkers. In particular, EGFR mutation and EML4/ALK testing have reached clinical validation and are incorporated into current treatment paradigms. This overview will present the scientific background of the biology of the relevant biomarkers and the studies conducted for their clinical validation. The technical challenges and shortcomings of these assays are also discussed. Furthermore, ongoing biomarker-driven clinical studies and the appropriate clinical use of available tests will be reviewed to assist the clinician with the proper incorporation of molecular testing into the routine care of patients with non-small cell lung cancer.

KW - Biomarkers

KW - EGFR

KW - EML4/ALK translocation

KW - KRAS

KW - Molecular testing

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=77956266461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956266461&partnerID=8YFLogxK

U2 - 10.1007/s11912-010-0118-z

DO - 10.1007/s11912-010-0118-z

M3 - Article

VL - 12

SP - 335

EP - 348

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

ER -